SCHEMBL20949059

SCHEMBL20949059

CC(C)CN1CCC(C(=O)Nc2cc3cc(-c4cn[nH]c4)ncc3cn2)CC1

nearest known ligand 0.83

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 20/20 0.83
DYRK1A Q13627 20/20 0.83
WNT1 P04628 17/20 0.83
DYRK3 O43781 1/20 0.60
CLK1 P49759 1/20 0.60
CLK2 P49760 1/20 0.60
CLK3 P49761 1/20 0.60
CDK5 Q00535 1/20 0.60
CDK5R1 Q15078 1/20 0.60
DYRK2 Q92630 1/20 0.60
CLK4 Q9HAZ1 1/20 0.60
DYRK4 Q9NR20 1/20 0.60
DYRK1B Q9Y463 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30005417 0.91 GSK3B (1.00) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL19516166 0.91 GSK3B (1.00) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL20950215 0.86 GSK3B (0.79) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL20951976 0.86 DYRK1A (0.79) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL20948878 0.84 GSK3B (0.80) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL19516118 0.84 GSK3B (0.86) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL19516119 0.84 GSK3B (0.86) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL19516137 0.84 GSK3B (0.86) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL30004740 0.84 GSK3B (0.86) GSK3BDYRK1AWNT1DYRK3CLK1
SCHEMBL30005595 0.84 GSK3B (0.86) GSK3BDYRK1AWNT1DYRK3CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US claimed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US claimed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 GSK3B 19/4885DYRK1A 1/4885WNT1 3/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 GSK3B 19/4885DYRK1A 1/4885WNT1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.